Skip to main content
European Commission logo print header

Mutant p53 gain of function activities as determinants for tumor prognosis and therapy

Objetivo

P53 gene mutations are common in cancer. Human tumors accumulate abundant mutant p53 protein. Wild type (wt) p53 is a potent tumor supressor. In addition to loosing the inhibitory functions of wt p53, cancer-associated mutant p53 may gain new oncogenic functions to actively promote cancer. Wt p53 is studied extensively, but little is known about gain of function of mutant p53 and its relevance to cancer. Based on recent findings by the partners, we will explore biological effects of tumor-derived p53 mutants and their biochemical basis. We will use cell-free assays, cultured cells and mouse models. Different mutants will be compared. A special database will address correlations between mutant p53 status and patient outcome. Using a novel assay, chemical libraries will be screened for p53-inhibitory drugs. This should advance understanding of cancer etiology and define new therapy taegets.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

HEINRICH-PETTE-INSTITUT FUER EXPERIMENTELLE VIROLOGIE UND IMMUNOLOGIE AN DER UNIVERSITAET HAMBURG
Aportación de la UE
Sin datos
Dirección
Martinistrasse 52
HAMBURG
Alemania

Ver en el mapa

Enlaces
Coste total
Sin datos

Participantes (5)